Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous genetically-modified MAGE-A4 C1032 CD8alpha T cells

Autologous human T lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4) and the CD8alpha co-receptor, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous genetically-modified MAGE-A4 C1032 CD8alpha T cells bind to tumor cells expressing MAGE-A4. This may result in both inhibition of growth and increased cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T cells into CD8+ cytotoxic T cells.
Synonym:ADP-A2M4CD8
autologous genetically-modified MAGE-A4 C1032 CD8alpha T lymphocytes
autologous genetically-modified melanoma antigen A4 CD8alpha T cells
autologous MAGE-A4 C1032 TCR-modified CD8alpha T cells
autologous TCR-transduced MAGE-A4 C1032 CD8alpha T cells
MAGE-A4 SPEAR CD8alpha T cells
MAGE-A4 SPEAR CD8alpha T-cells
MAGE-A4-specific TCR gene-transduced C1032 CD8alpha T lymphocytes
MAGE-A4-specific TCR gene-transduced C1032 CD8alpha T-lymphocytes
SPEAR T-cell ADP-A2M4CD8
Search NCI's Drug Dictionary